Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis (RFPMDLS)

March 4, 2025 updated by: Xinyun li, The First People's Hospital of Yunnan

Prediction of Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis Based on Spine MRI

This is a retrospectively observational study. The goal of this observational study is to analyze the risk factors of paraspinal muscles associated with the occurrence of spondylolisthesis in patients with degenerative lumbar spondylolisthesis(DLS) and to construct a predictive model. The main question it aims to answer is: Which paraspinal muscle changes are risk factors for DLS? We will collect the information of patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.The collected data included gender, age, body mass index (BMI), diabetes, hypertension, occupation and imaging parameters. We will then retrospectively analyze the risk factors associated with lumbar spondylolisthesis.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Yunnan
      • Kunming, Yunnan, China, 650032
        • The First People's Hospital of Yunnan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.

Description

Inclusion Criteria:

  • Patients who presented to our hospital with back pain(the diagnosis was spondylolisthesis or no spondylolisthesis);
  • Patients older than 50 years;
  • Patients with complete clinical data and magnetic resonance imaging (MRI) before surgery.

Exclusion Criteria:

  • The patient has previous spinal surgery;
  • Patients with lumbar tumor,lumbar infection and lumbar tuberculosis;
  • Patients with incomplete MRI sequence.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group A
patients without lumbar spondylolisthesis
Group B
patients with lumbar spondylolisthesis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the MF FCSA
Time Frame: Two weeks before treatment
The functional cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
Two weeks before treatment
the ES FCSA
Time Frame: Two weeks before treatment
The functional cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
Two weeks before treatment
the MF CSA
Time Frame: Two weeks before treatment
the total cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
Two weeks before treatment
the ES CSA
Time Frame: Two weeks before treatment
the total cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
Two weeks before treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SMI
Time Frame: Two weeks before treatment
The skeletal muscle index.SMI = l CSA of muscle on an axial scan (expressed as cm2) divided by the square of the patient's height (expressed as cm2).
Two weeks before treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 6, 2025

Primary Completion (Estimated)

April 30, 2025

Study Completion (Estimated)

August 31, 2025

Study Registration Dates

First Submitted

January 23, 2025

First Submitted That Met QC Criteria

January 23, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 4, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • KHLL2025-KY047
  • 2024JSKFKT-17 (Other Grant/Funding Number: Yunnan Spinal Cord Disease Clinical Medical Center)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spine Degeneration

Subscribe